| INTRODUCTION
The color of human skin varies widely across the globe and is classified into six subtypes based on burning and tanning after UV exposure. 1 The color of our skin is due largely to the pigment melanin, produced by melanocytes residing in the basal layer of the epidermis. The process of melanin biosynthesis and its distribution throughout the skin is regulated by complex processes involving several enzymes in melanocytes located in melanosomes. 2 A review from Ebanks et al 3 summarizes some well-established intrinsic and extrinsic factors which act as modulators for various melanogenic pathways. Melanosomes are then transferred to keratinocytes where Neu5Acα(2-6)Gal-terminated and possibly sialyl(α2-3)gal-terminated glycans play significant roles. 4 Diwakar et al 4 studied the inhibitory effects of cytidine, 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL) on melanin synthesis and transfer process. Cytidine was pursued as a safe, efficacious, and commercially viable option over 6′-SL and 3′-SL. From a cosmetic and pharmaceutical perspective, the quest for the next generation of melanogenic modulators is not only focused on finding new ingredients affecting the existing mechanisms but also on exploring new mechanisms which affect the melanogenic pathways. Here, we evaluated the effects of cytidine on lightening of hyperpigmented regions of female skin in a dose-dependent, double-blind, vehicle-controlled clinical study. In vitro skin penetration studies were also conducted to evaluate the effect of the formulations on skin penetration of cytidine.
| MATERIALS AND METHODS

| Materials
| Cytidine
Cytidine was obtained from Shanghai Sharing Technologies Co. Ltd.
(Shanghai, China), with a purity of ≥99%. The physicochemical properties of cytidine are listed in Table 1 .
| Lotion base
The lotion base was formulated with following ingredients: water, squalene, butylene glycol, dipropylene glycol, cetyl palmitate, behenyl alcohol, glyceryl stearate, glycerin, PPG-4-ceteth-20, diphenyl dimethicone, beheneth-10, hydroxyethylcellulose, xanthan gum, hydrogenated lecithin, phenoxyethanol, methylparaben, chlorphenesin, and sodium hyaluronate.
| Control and test formulations
The lotion base served as the vehicle control formulation. Test formulations A, B, and C with cytidine at 2%, 3%, and 4% (w/w), respectively, were formulated in the lotion base. Accelerated stability testing of all the formulations was conducted at 4.5°C for 3 months, 25 and 40°C for 6 months, and 50°C for 1 month. All the formulations were physically and chemically stable.
| Methods
| Clinical study protocol
The clinical study was conducted by DERMAPRO Ltd in Seoul, aged from 20 to 60 years old with hyperpigmented areas on the face were recruited for the study. The number of female subjects in each study group and their average ages are summarized in Table 2 .
The study was conducted between months of December and March.
All the subjects were monitored for any adverse skin reactions.
| Application method
After washing their face, the subjects applied the vehicle control lotion on one side (vertical half) of the face, and a cytidine-containing lotion (A, B, or C) was applied to the other side. The lotions were applied two times a day (morning and evening), every day throughout the 12-week study. Subjects in each of the three test groups were divided into two subgroups to double-blind the application of vehicle control and test formulation on left or right side of the face.
| Visual assessment
Two expert clinical graders at DERMAPRO Ltd performed the visual assessment of hyperpigmented skin by following a 0-9 scoring T A B L E 1 Physicochemical properties of cytidine 18, 19 Common name Cytidine grades. The subjects were visually graded before the treatment, at 6 and 12 weeks after the treatment.
| Melanin index measurement
The melanin index was measured by using a Mexameter® MX18
(C + K electronic GmbH Inc, Cologne, Germany) on the hyperpigmented area. The measurements were done in triplicate before the treatment and at 6 and 12 weeks after the treatment.
| Skin brightness measurement (L*) and skin color analysis (ITA o )
The skin color parameters L* (brightness, luminance parameter), a* 
| In vitro Franz cell study
In vitro Franz diffusion cell studies were performed using excised, ) facing the donor chamber. DPBS with 0.05% (w/ v) sodium azide was used as the receptor solution (5 mL). The water jacketed receptor chamber was maintained at 32°C along with continuous mixing using a magnetic stirring bar. The integrity of the skin samples was measured by performing skin resistance measurements made with a custom-built setup as described by Baswan et al. 8, 9 Skin resistance measurements were performed under partially hydrated conditions, and measurements were performed after 30-minute submersion under DPBS. The use of low current and frequency conditions ensured that the measurements were primarily resistive and not capacitive. 8, 9 Skin samples with a resistance of <50 kΩ were discarded and replaced with new skin samples and screened again. All the tissue samples were measured to have the resistance in the range of 75-110 kΩ. Although the inherent skin variability cannot be eliminated by any screening method, this ensures that the significantly damaged skin tissue samples not visible to the naked eye do not contribute to the highly variable dataset.
After a 24-hour period, to achieve equilibrium, the receptor DPBS solution was replaced with fresh DPBS solution. The donor compartments (n = 6) were dosed with 25µL of 2% cytidine formulation which translates to an applied dose of 781 µg/cm 2 . After a 24-hour period, the skin samples were rinsed three times with 1 mL DPBS solution, and the residual formulation was removed by Q-tips®. One D-Squame® tape strip (Cuderm Corp., Dallas, TX, USA) was performed to remove any residual formulation over the stratum corneum. The stratum corneum and epidermis were separated physically by using forceps and were desorbed in 5 mL DPBS solution for 48 hours on a horizontal plate shaker. The desorbed stratum corneum solution, epidermis solution, and receptor compartment solution were quantified by liquid chromatography-mass spectrometry (detection limit-6 ng/mL).
| DATA ANALYSIS
Statistical analyses were conducted using the SPSS ® software pro- 
| Visual assessment scores
For group A ( Figure 1A) , the visual assessment scores of the test site in comparison with the before treatment on the same site showed a significant decrease after 6-and 12-week treatment (P < 0.05).
There was no change on the placebo control side. The visual scores of the test site were significantly lower than the control site at 6 and 12 weeks (P < 0.05). Similar trends were observed for visual scores for group B ( Figure 1B ) and group C ( Figure 1C ) except the control site for group B which showed significant improvement in visual scores in comparison with before treatment.
| Melanin index
For all the three groups A, B, and C ( 
| L* (skin brightness) value
For all the three groups A, B, and C ( Figure 3A-C, respectively) , the L* values of the test site in comparison with the before treatment on the same site showed a significant increase after 6 and 12 weeks treatment (P < 0.05). The control site also showed a significant difference in L* value after 6 (P < 0.05) and 12 weeks (P < 0.05) when control vs 3% cytidine, and (C) control vs 4% cytidine. *Significantly different at P < 0.05 compared with before treatment on the same site.
† Significantly different at P < 0.05 compared between two groups (test vs control) compared to the same site before treatment. However, the L* value of the test site of all the three groups was significantly higher than the control site at 6 (P < 0.05) and 12 weeks (P < 0.05).
| Skin color analysis (ITA o value)
The ITA o values for the test site for all the three groups A, B, and C ( Figure 4A -C, respectively) in comparison with the before treatment (on the same site) showed significant increases after 6-(P < 0.05) and 12-week treatment (P < 0.05). The control site also showed a significant difference in ITA o value after 6 and 12 weeks of treatment when compared to the same site before treatment. However, the ITA o value of the test site of group A and group C was significantly higher than the control site at 6 (P < 0.05) and 12 weeks (P < 0.05).
| Photographic analyses
Photographs of two selected subjects during 0, 6, and 12 weeks of cytidine treatment are shown in Figure 5 (circled areas). Both subjects showed lightening in a time-dependent fashion.
| DISCUSSION AND CON CLUSIONS
A dose-dependent effect of cytidine on skin lightening was evident from the changes in clinical parameters except for visual grading by a specific delivery route. In the case of cytidine, the site of action is the epidermal-dermal junction where the majority of the melanocytes reside. Thus, the clinically active concentration of cytidine is anticipated to be between 10 and 40 µM/L. 4 Although no detectable levels of cytidine were found in the epidermis layer and the receptor compartment, the presence of cytidine in stratum corneum was 9-fold higher (361 µM/L) than the presumed clinically active (site of action) concentration (40 µM/L). This suggests that the stratum corneum can act as a potential depot for a sustained release of cytidine. The lower skin absorption of cytidine (361 µM) relative to the dose concentration of 82.2 mM could partially be attributed to the hydrophilic properties of cytidine which do not lend itself as a favorable candidate for permeation across the lipophilic stratum corneum. Also, the absence of permeation enhancement by the formulation could limit its penetration through the lipophilic region. Since the primary route of absorption of cytidine is likely to be through the polar pathway, this would represent a small fraction of total permeation from the entire skin diffusion routes. 15, 16 This suggests formulating a more efficient delivery system would enhance the lightening efficacy of cytidine at lower doses.
In topical application clinical studies, the influence of factors such as seasonal changes in skin color, the effects of the contents of the formulation, subject compliance, study design, and variability associated with observer scoring is well known. Some of these factors will inherently be an inseparable part of the study, whereas others can be controlled by designing better clinical protocols.
The control and test formulations were formulated to exclude ingredients known to influence skin pigmentation. For example, the use of lecithin, an excipient that is a commonly used emulsifier/co-emulsifier in cosmetic formulations, was kept to a minimum (<0.1%) because lecithin can inhibit melanosome transfer. 7 Pigmentary spots such as melasma, solar lentigines, and post-inflammatory hyperpigmentation (PIH) are known to darken with high UV exposure during summer and lighten during the winter with reduced UV exposure. 7 The average UV index in the city of Seoul between July 2016 and July 2017 is shown in Figure 6 . As this study was conducted during the winter period (December-March), it ensured that the sun tanning and the melanin content of the skin were at a minimum.
Thus, the observed clinical results could be more conclusively associated with the efficacy of cytidine than the seasonal lightening of the skin.
In conclusion, this randomized, double-blind, 12-week clinical study successfully demonstrated the efficacy of cytidine on skin depigmentation in a dose-dependent manner. The in vitro skin penetration tests indicated that further enhancement of the clinical efficacy could be achieved at lower concentrations of cytidine by designing new skin penetration formulations.
| STATEMENT OF CONSEN T
The informed consent form which detailed the purpose and procedures of the study, schedule, compensation, and anticipated side effects was voluntarily signed by all the participants in the study before the commencement of the study.
F I G U R E 6
Average UV index in the city of Seoul, South Korea, from July 2016 to July 2017
